|Mr. Jeffrey R. Baxter F.C.M.A., FCMA||Pres, CEO & Director||780.27k||N/A||1961|
|Dr. David Evander Anderson||Chief Scientific Officer||461.14k||N/A||1970|
|Dr. Francisco Diaz-Mitoma||Chief Medical Officer||530.89k||N/A||1955|
|Mr. Christopher McNulty||CFO, Head of Bus. Devel. & Director||N/A||N/A||1977|
|Ms. Athena Kartsaklis||Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer||N/A||N/A||1965|
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus. It is also developing cytomegalovirus vaccine candidate for infectious disease; and glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts.
VBI Vaccines Inc.’s ISS Governance QualityScore as of December 2, 2019 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 4; Compensation: 7.